Recurrent Chordoma
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors (NCT05286801) | National Cancer Institute (NCI) | 2022-11-17 |
Track Recurrent Chordoma automatically
Every clearance here is in the API, with alerts when new ones post.